Trial Information

Study of the Prevalence of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease.

As one of the most common cancer worldwide, colorectal cancer (CRC) is a major cause of
cancer death in Asian countries. And during the past three decades, the incidence of CRC has
been increasing rapidly in china. Many studies supported that cigarette smoking, obesity and
insulin resistance were associated with CRC. In recent years, metabolic syndrome (MetS)
- Including glucose tolerance, dyslipidemia, obesity, hypertension and chronic inflammation -
and its individual components have been proven to be the risk for colorectal neoplasm.
Colonoscopy is the most accurate technique for diagnosis, surveillance and exclusion of
colorectal neoplasm for high-risk CRC groups. Therefore, improved risk stratification
knowledge of the target population is necessary to improve CRC patients' prognosis.

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease
worldwide and cause a wide spectrum of liver damage, such as steatohepatitis, cirrhosis,
even end-stage liver disease and hepatocellular carcinoma. NAFLD has been found to be
associated with obesity, insulin resistance, hypertension and dyslipidemia, and is
considered as a liver manifestation of MetS. Although it has been also well established that
MetS and its individual components are risk factors for colorectal neoplasm, as above, there
is paucity of research looking at the relation between NAFLD and CRC. Therefore, the
investigators aimed to investigate the prevalence of CRC in patients with NAFLD and evaluate
whether NAFLD is an independent risk factor for CRC.